Kindred Biosciences (Kindred Biosciences) Cash-to-Debt : 3.20 (As of Jun. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Kindred Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kindred Biosciences's cash to debt ratio for the quarter that ended in Jun. 2021 was 3.20.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Kindred Biosciences could pay off its debt using the cash in hand for the quarter that ended in Jun. 2021.

The historical rank and industry rank for Kindred Biosciences's Cash-to-Debt or its related term are showing as below:

KIN' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.38 Med: No Debt Max: No Debt
Current: 3.2

During the past 9 years, Kindred Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 2.38. And the median was No Debt.

KIN's Cash-to-Debt is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.945 vs KIN: 3.20

Kindred Biosciences Cash-to-Debt Historical Data

The historical data trend for Kindred Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kindred Biosciences Cash-to-Debt Chart

Kindred Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

3.18

2.50

Kindred Biosciences Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Cash-to-Debt	Get a 7-Day Free Trial															2.94	2.66	2.50	2.71	3.20

Competitive Comparison of Kindred Biosciences's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Kindred Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kindred Biosciences's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kindred Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kindred Biosciences's Cash-to-Debt falls into.

Kindred Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kindred Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	58.378	/	(1.936	+	21.436)
	=	2.50

Kindred Biosciences's Cash to Debt Ratio for the quarter that ended in Jun. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	74.199	/	(5.383	+	17.843)
	=	3.19

Kindred Biosciences (NAS:KIN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Kindred Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kindred Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kindred Biosciences (Kindred Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kindred Biosciences Inc (NAS:KIN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1555 Bayshore Highway, Suite 200, Burlingame, CA, USA, 94010

Website

https://www.kindredbio.com

Kindred Biosciences Inc is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. The company identifies targets that have already demonstrated safety and efficacy in humans and develop therapeutics based on these validated targets for dogs and cats. It has a pipeline of novel biologics in development across many therapeutic classes, alongside biologics manufacturing capabilities and a broad intellectual property portfolio.

Executives

Richard Chin	director, officer: Chief Executive Officer	C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Park West Asset Management Llc	10 percent owner	1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Denise Bevers	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Wendy Wee	officer: Chief Financial Officer	C/O TELIK, INC. 700 HANSEN WAY PALO ALTO CA 94304
Hangjun Zhan	officer: Chief Scientific Officer	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Joseph S Mccracken	director	C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Herbert D Montgomery	director	C/O ATKINSON 1001 BAYHILL DRIVE 2ND FL SAN BRUNO CA 94066
Raymond Townsend	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ervin Veszpremi	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Stephen Sundlof	officer: SVP of Regulatory Affairs	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Oleg Nodelman	director	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Selby Blake Hawley	officer: Chief Commercial Officer	C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010
Stephen S Galliker	officer: Chief Financial Officer	300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Kevin Schultz	officer: Chief Scientific Officer	C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010